Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Foster

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The American Journal of Gastroenterology|October 10, 2006
Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancersFrank A Sinicrope, Rafaela L Rego, Nathan Foster, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2005
A plasma membrane H+-ATPase is required for the formation of proanthocyanidins in the seed coat endothelium of Arabidopsis thalianaIvan R Baxter, Jeffery C Young, Gordon Armstrong, et al.
The Journal of Supportive Oncology|February 3, 2007
Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinomaAminah Jatoi, Phuong L Nguyen, Nathan Foster, et al.
American Journal of Clinical Oncology|June 7, 2006
Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancerJulian R Molina, James R Jett, Nathan Foster, et al.
Gastroenterology|September 6, 2006
Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patientsFrank A Sinicrope, Rafaela L Rego, Kevin C Halling, et al.
JAMA Network Open|October 24, 2024
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538Michael K Farris, Michael D Mix, Xiaofei Wang, et al.
Immunotherapy|April 21, 2021
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)Jacob M Sands, Sumithra J Mandrekar, David Kozono, et al.
The Oncologist|June 20, 2023
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract CarcinomaSri Harsha Tella, Nathan Foster, Shi Qian, et al.
The Lancet. Oncology|September 4, 2025
De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trialDaniel Ma, Katharine Price, Eric Moore, et al.
Gut|May 31, 2022
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposisN Jewel Samadder, Nathan Foster, Ryan P McMurray, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The American Journal of Gastroenterology|October 10, 2006
Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancersFrank A Sinicrope, Rafaela L Rego, Nathan Foster, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2005
A plasma membrane H+-ATPase is required for the formation of proanthocyanidins in the seed coat endothelium of Arabidopsis thalianaIvan R Baxter, Jeffery C Young, Gordon Armstrong, et al.
The Journal of Supportive Oncology|February 3, 2007
Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinomaAminah Jatoi, Phuong L Nguyen, Nathan Foster, et al.
American Journal of Clinical Oncology|June 7, 2006
Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancerJulian R Molina, James R Jett, Nathan Foster, et al.
Gastroenterology|September 6, 2006
Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patientsFrank A Sinicrope, Rafaela L Rego, Kevin C Halling, et al.
JAMA Network Open|October 24, 2024
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538Michael K Farris, Michael D Mix, Xiaofei Wang, et al.
Immunotherapy|April 21, 2021
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)Jacob M Sands, Sumithra J Mandrekar, David Kozono, et al.
The Oncologist|June 20, 2023
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract CarcinomaSri Harsha Tella, Nathan Foster, Shi Qian, et al.
The Lancet. Oncology|September 4, 2025
De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trialDaniel Ma, Katharine Price, Eric Moore, et al.
Gut|May 31, 2022
Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposisN Jewel Samadder, Nathan Foster, Ryan P McMurray, et al.
Pageof 2